<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    7955452
   </pmid>
   <datecreated>
    <year>
     1994
    </year>
    <month>
     12
    </month>
    <day>
     19
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1994
    </year>
    <month>
     12
    </month>
    <day>
     19
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0300-0664
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       41
      </volume>
      <issue>
       4
      </issue>
      <pubdate>
       <year>
        1994
       </year>
       <month>
        Oct
       </month>
      </pubdate>
     </journalissue>
     <title>
      Clinical endocrinology
     </title>
     <isoabbreviation>
      Clin. Endocrinol. (Oxf)
     </isoabbreviation>
    </journal>
    <articletitle>
     Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism.
    </articletitle>
    <pagination>
     <medlinepgn>
      421-4
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      There is recent evidence that both exogenous and endogenous subclinical thyrotoxicoses are associated with decreased bone mineral density. Scanty information is available on bone metabolism in these conditions when euthyroidism is restored. We evaluated the effect of anti-thyroid drug treatment on bone metabolism in endogenous subclinical hyperthyroidism.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Prospective follow-up study over 2 years during treatment with methimazole, with an untreated control group.
     </abstracttext>
     <abstracttext label="SUBJECTS" nlmcategory="METHODS">
      Sixteen post-menopausal women with endogenous subclinical hyperthyroidism associated with multinodular goitre, eight of whom were treated with methimazole.
     </abstracttext>
     <abstracttext label="MEASUREMENTS" nlmcategory="METHODS">
      Serum concentrations of free T4, total T3, TSH, osteocalcin, urinary excretion of hydroxyproline and forearm bone mineral density were measured at regular intervals.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Significant changes in serum osteocalcin concentration or urinary hydroxyproline excretion were not observed in either group. Distal, but not proximal, forearm bone mineral density, expressed as a percentage of the base-line value, was significantly (P &lt; 0.05) higher in the treated than in the untreated subjects in the second year of treatment.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Treatment with methimazole in post-menopausal women with endogenous subclinical hyperthyroidism associated with multinodular goitre can prevent excessive loss of bone, at least in the distal forearm.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Internal Medicine, Slingeland Ziekenhuis, Doetinchem, The Netherlands.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Mudde
      </lastname>
      <forename>
       A H
      </forename>
      <initials>
       AH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Houben
      </lastname>
      <forename>
       A J
      </forename>
      <initials>
       AJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Nieuwenhuijzen Kruseman
      </lastname>
      <forename>
       A C
      </forename>
      <initials>
       AC
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     Clin Endocrinol (Oxf)
    </medlineta>
    <nlmuniqueid>
     0346653
    </nlmuniqueid>
    <issnlinking>
     0300-0664
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      104982-03-8
     </registrynumber>
     <nameofsubstance>
      Osteocalcin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      51-35-4
     </registrynumber>
     <nameofsubstance>
      Hydroxyproline
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      60-56-0
     </registrynumber>
     <nameofsubstance>
      Methimazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      6893-02-3
     </registrynumber>
     <nameofsubstance>
      Triiodothyronine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      7488-70-2
     </registrynumber>
     <nameofsubstance>
      Thyroxine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      9002-71-5
     </registrynumber>
     <nameofsubstance>
      Thyrotropin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bone Density
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bone and Bones
     </descriptorname>
     <qualifiername majortopicyn="Y">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Forearm
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Goiter
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="N">
      urine
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hydroxyproline
     </descriptorname>
     <qualifiername majortopicyn="N">
      urine
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hyperthyroidism
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Methimazole
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Osteocalcin
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Postmenopause
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="N">
      urine
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thyrotropin
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thyroxine
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Triiodothyronine
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1994
     </year>
     <month>
      10
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1994
     </year>
     <month>
      10
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1994
     </year>
     <month>
      10
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     7955452
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

